An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

Eppie M Yiu, Geneieve Tai, Roger E Peverill, Katherine J Lee, Kevin D Croft, Trevor A Mori, Barbara Scheiber-Mojdehkar, Brigitte Sturm, Monika Praschberger, Adam P. Vogel, Gary Rance, Sarah E M Stephenson, Joseph P Sarsero, Creina Stockley, Chung-Yung J. Lee, Andrew Churchyard, Marguerite V Evans-Galea, Monique M Ryan, Paul J Lockhart, Louise A CorbenMartin B Delatycki

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)

Abstract

Friedreich ataxia (FRDA) is due to a triplet repeat expansion in FXN, resulting in deficiency of the mitochondrial protein frataxin. Resveratrol is a naturally occurring polyphenol, identified to increase frataxin expression in cellular and mouse models of FRDA and has anti-oxidant properties. This open-label, non-randomized trial evaluated the effect of two different doses of resveratrol on peripheral blood mononuclear cell (PBMC) frataxin levels over a 12-week period in individuals with FRDA. Secondary outcome measures included PMBC FXN mRNA, oxidative stress markers, and clinical measures of disease severity. Safety and tolerability were studied. Twenty-four participants completed the study; 12 received low-dose resveratrol (1 g daily) and 12 high-dose resveratrol (5 g daily). PBMC frataxin levels did not change in either dosage group [low-dose group change: 0.08 pg/mug protein (95 CI -0.05, 0.21, p = 0.21); high-dose group change: 0.03 pg/mug protein (95 CI -0.10, 0.15, p = 0.62)]. Improvement in neurologic function was evident in the high-dose group [change in Friedreich Ataxia Rating Scale -3.4 points, 95 CI (-6.6, -0.3), p = 0.036], but not the low-dose group. Significant improvements in audiologic and speech measures, and in the oxidative stress marker plasma F2-isoprostane were demonstrated in the high-dose group only. There were no improvements in cardiac measures or patient-reported outcome measures. No serious adverse events were recorded. Gastrointestinal side-effects were a common, dose-related adverse event. This open-label study shows no effect of resveratrol on frataxin levels in FRDA, but suggests that independent positive clinical and biologic effects of high-dose resveratrol may exist. Further assessment of efficacy is warranted in a randomized placebo-controlled trial.
Original languageEnglish
Pages (from-to)1344-1353
Number of pages10
JournalJournal of Neurology
Volume262
Issue number5
DOIs
Publication statusPublished - 7 Apr 2015

Cite this

Yiu, E. M., Tai, G., Peverill, R. E., Lee, K. J., Croft, K. D., Mori, T. A., Scheiber-Mojdehkar, B., Sturm, B., Praschberger, M., Vogel, A. P., Rance, G., Stephenson, S. E. M., Sarsero, J. P., Stockley, C., Lee, C-Y. J., Churchyard, A., Evans-Galea, M. V., Ryan, M. M., Lockhart, P. J., ... Delatycki, M. B. (2015). An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Journal of Neurology, 262(5), 1344-1353. https://doi.org/10.1007/s00415-015-7719-2